Trial · NCT03112603
Results by group169
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 169
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit | Ruxolitinib | 49.7 | 95% Confidence Interval 41.8 to 57.6 | percentage of participants | |
Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit | Best Available Therapy | 25.6 | 95% Confidence Interval 19.1 to 33.0 | percentage of participants | |
| Rate of Participants With Clinically Relevant Improvement of the Modified Lee cGvHD Symptom Scale Score | Ruxolitinib | 24.2 | 95% Confidence Interval 17.9 to 31.5 | percentage of participants | |
| Rate of Participants With Clinically Relevant Improvement of the Modified Lee cGvHD Symptom Scale Score | Best Available Therapy | 11.0 | 95% Confidence Interval 6.6 to 16.8 | percentage of participants | |
| Rate of Failure-free Survival (FFS) | Ruxolitinib | NA | 95% Confidence Interval 18.6 to NA | months | |
| Rate of Failure-free Survival (FFS) | Best Available Therapy | 5.7 | 95% Confidence Interval 5.6 to 6.5 | months | |
| Rate of FFS at Study Completion | Ruxolitinib | 38.4 | 95% Confidence Interval 22.1 to NA | months | |
| Rate of FFS at Study Completion | Best Available Therapy | 5.7 | 95% Confidence Interval 5.6 to 6.5 | months | |
| Best Overall Response (BOR) at Cycle 7 Day 1 | Ruxolitinib | 76.4 | 95% Confidence Interval 69.1 to 82.6 | percentage of participants | |
| Best Overall Response (BOR) at Cycle 7 Day 1 | Best Available Therapy | 60.4 | 95% Confidence Interval 52.4 to 67.9 | percentage of participants | |
| BOR During Cross-over Treatment With Ruxolitinib | Ruxolitinib Cross-Over Period | 81.4 | 95% Confidence Interval 70.3 to 89.7 | percentage of participants | |
| ORR at the End of Cycle 3 | Ruxolitinib | 54.5 | 95% Confidence Interval 46.6 to 62.3 | percentage of participants | |
| ORR at the End of Cycle 3 | Best Available Therapy | 31.1 | 95% Confidence Interval 24.1 to 38.8 | percentage of participants | |
| Duration of Response Through Study Completion | Ruxolitinib | NA | 95% Confidence Interval NA to NA | Months | |
| Duration of Response Through Study Completion | Best Available Therapy | 6.4 | 95% Confidence Interval 4.9 to 11.4 | Months | |
| Overall Survival (OS) | Ruxolitinib | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival (OS) | Best Available Therapy | NA | 95% Confidence Interval 41.0 to NA | months | |
| Cumulative Incidence of Non-relapse Mortality (NRM) | Ruxolitinib | Month 3 | 5.45 | 95% Confidence Interval 2.68 to 9.67 | percentage of participants |
| Cumulative Incidence of Non-relapse Mortality (NRM) | Best Available Therapy | Month 3 | 4.44 | 95% Confidence Interval 1.96 to 8.48 | percentage of participants |
| Cumulative Incidence of Non-relapse Mortality (NRM) | Ruxolitinib | Month 6 | 9.13 | 95% Confidence Interval 5.34 to 14.15 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03112603/results